International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2025 (WCLC 2025)
Barcelona, Spain 06 September 2025 - 09 September 2025
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
30 Sep 2025
byAudrey Abella
Results from the phase III HARMONi trial presented at WCLC 2025 show that adding ivonescimab to chemotherapy prolongs progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
30 Sep 2025
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
29 Sep 2025
byAudrey Abella
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.